Helomics is a clinical contract research organization. It utilizes a tumor drug response profiling platform to generate a roadmap helping oncologists personalize the patient’s treatment.

Employee Rating

2.7More
TypeSubsidiary
Parent CompanyPredictive Oncology
HQPittsburgh, PA, US
Websitehelomics.com
Cybersecurity ratingBMore
Helomics is headquartered in Pittsburgh, PA, US

Viewing summary data as a guest

Sign up for free to see all data

Helomics Office Locations

Helomics has an office in Pittsburgh
Pittsburgh, PA, US (HQ)
91 43rd St #110
Show all (1)

Helomics Financials and Metrics

Summary Metrics

Total Funding

$231.5 m

Investors

In total, Helomics had raised $231.5 m. Helomics is a subsidiary of Predictive Oncology

Helomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Helomics Online and Social Media Presence

Embed Graph

Helomics News and Updates

Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes

Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the …

POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer

Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building

Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer

MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian …

Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?’

LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of…

Helomics Blogs

Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment

MINNEAPOLIS, Minn., June 26, 2019 (GLOBE NEWSWIRE) – Predictive Oncology(Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement with Pi…

Helomics Frequently Asked Questions

  • How many employees does Helomics have?

    Helomics has 80 employees.

  • Who are Helomics competitors?

    Competitors of Helomics include Personalis, MTM and Datos Health.

  • Where is Helomics headquarters?

    Helomics headquarters is located at 91 43rd St #110, Pittsburgh.

  • Where are Helomics offices?

    Helomics has an office in Pittsburgh.

  • How many offices does Helomics have?

    Helomics has 1 office.